Artiva Biotherapeutics Appoints Experienced Biotech Veteran Thad Huston as New CFO
Summary
Artiva Biotherapeutics has appointed Thad Huston, a seasoned finance executive with over 30 years of experience in the biotech and pharmaceutical sectors, as its new Chief Financial Officer, effective February 18, 2026.
Key Events
-
New Chief Financial Officer Appointed
Thad Huston has been appointed as the Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective February 18, 2026.
-
Extensive Industry Experience
Mr. Huston possesses over 30 years of global leadership experience in finance, commercial strategy, business development, and operations across public pharmaceutical, biotechnology, and medical device companies, including prior CFO roles at Galapagos NV and LivaNova PLC.
-
Compensation Package Detailed
Mr. Huston will receive an annual base salary of $540,000, a target annual cash bonus of 40% of his base salary, and an inducement award of 220,000 restricted stock units (RSUs) vesting over four years.
Analysis
Artiva Biotherapeutics has appointed Thad Huston as its new Chief Financial Officer, a critical leadership role for a life sciences company. Mr. Huston brings over 30 years of extensive global finance, commercial strategy, and operational experience from prominent biotechnology and pharmaceutical companies, including prior CFO roles. This appointment signals a strategic move to strengthen financial leadership and operational capabilities. The significant inducement award of 220,000 restricted stock units aligns Mr. Huston's incentives with long-term shareholder value, demonstrating the company's commitment to attracting top talent.
At the time of this filing, ARTV was trading at $4.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $123.2M. The 52-week trading range was $1.47 to $7.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.